Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors.
Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, it has entered a collaboration to evaluate its lead candidate NY-ESO SPEAR T-cell therapy in combination with MSD’s Keytruda (pembrolizumab).
Adaptimmune will sponsor the trial aimed at multiple myeloma, a form of blood cancer that affects plasma cells with high rates of relapse. Its SPEAR technology uses genetically optimized TCRs that recognize the NY-ESO tumor antigen. The therapy already has positive results from Phase I/II in multiple myeloma and also in synovial sarcoma, which Adaptimmune is tackling in collaboration with GSK.
MSD’s Keytruda is an antibody therapy that blocks the checkpoint inhibitor PD-L1, a tumor protein that binds to the PD-1 receptors of T-cells and inhibits the immune response.